arrow
C

Cristina Flores

centro de doenças inflamatórias intestinais e imunomediadas
H指数:16
被引数:1,147

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prior Exposure to Biologics and its Impact on Outcomes in Ulcerative Colitis: An Integrated Analysis of a Brazilian Cohort

既往生物制剂暴露及其对溃疡性结肠炎结局的影响:一项巴西队列的整合分析

2025-12-010
PRE
Real-World Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Retrospective Cohort Study

奥博珠单抗在溃疡性结肠炎患者中的真实世界有效性与安全性:一项回顾性队列研究

2025-10-010
OAAI
Defining Fecal Calprotectin Cutoffs That Predict Endoscopic and Histologic Remission in Patients With Ulcerative Colitis

Drügg Hahn, G.; Lakatos, P.L.; Maedler-Kron, C.; Marcus, V.; Afif, W.; Wild, G.; Bitton, A.; Flores, C.; Francesconi, C.F.d.M.; Bessissow, T. 定义可预测溃疡性结肠炎患者内镜和组织学缓解的粪钙卫蛋白截断值。Inflamm. Bowel Dis. 2025, 31, 2977–2985. [Google Scholar] [CrossRef]

2025-09-010
PRE
Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety

托法替尼治疗溃疡性结肠炎的巴西研究:一项关于有效性和安全性的多中心观察性研究

2025-03-180
OA
Factors Associated with the Optimization of Biological Therapy in Crohn's Disease and Ulcerative Colitis: Insights from the National GEDIIB Patient Registry in Brazil
2025-01-220
PRE
Analysis of Fistula Cases in Crohn's Disease Patients from Brazilian National GEDIIB Registry
2024-12-010
OA
Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study
2024-12-010
OA
Clinical Profile of Patients With Inflammatory Bowel Disease in Brazil: Analysis of the National Registry (GEDIIB)
2023-12-010
OA
Efficacy of Early Optimization of Infliximab Guided by Therapeutic Drug Monitoring during Induction-A Prospective Trial
2023-06-193
OAAI
Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil
2021-06-213
OAAI
Anti-TNF therapy for Ulcerative Colitis in Brazil: a comparative real-world national multicentric study from the Brazilian Study Group of IBD (GEDIIB)
2021-05-270
PRE
Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil
2021-01-1415
OAAI
Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil
2019-10-1462
OAAI